Psoriasis Treatment Market Research Report, 2026-31 Market Analysis

The global psoriasis treatment landscape has undergone significant transformation in the last five years, moving from broad-spectrum immunosuppressants toward targeted biologics and oral therapies with improved safety profiles. In 2024, the U.S. FDA approved Arcutis Biotherapeutics’ Zoryve (roflumilast) topical foam for both adult and pediatric plaque psoriasis, marking the first steroid-free topical therapy effective for scalp and body lesions. Shortly after, Tremfya (guselkumab) received pediatric approval for children aged six and older, addressing a previously underserved population and expanding treatment accessibility. The oral TYK2 inhibitor deucravacitinib by Bristol Myers Squibb further illustrated the market’s shift toward non-injectable targeted therapy for moderate-to-severe psoriasis, with post-marketing studies showing sustained PASI 75 and PASI 90 responses. Meanwhile, long-term data from UCB’s Bimzelx (bimekizumab) demonstrated durable skin clearance over multiple years, influencing physician confidence in biologic therapy for long-term management. The introduction of biosimilars has also reshaped the treatment environment: Teva and Alvotech launched SELARSDI (ustekinumab-aekn) in the U.S., while European markets saw adoption of Pyzchiva, increasing affordability and patient access. Digital tools, including teledermatology platforms accelerated during the COVID-19 pandemic, are now routinely used in follow-up care across the UK and Australia, allowing more frequent monitoring and improving adherence. These developments show a historic pivot from symptom-focused approaches toward evidence-based, precision-targeted therapies, broader age inclusion, and innovative administration methods, reflecting a market that is clinically mature yet still dynamically evolving. According to the research report, “Global Psoriasis Treatment Market Research Report, 2031” published by Actual Market Research, the Global Psoriasis Treatment market is expected to cross USD 50.59 Billion market size by 2031, with 9.27% CAGR by 2026-31.Recent activity in the global psoriasis treatment market highlights innovation through approvals, lifecycle management, and strategic industry partnerships.

The FDA’s approval of Zoryve foam offered patients a non-steroidal option, while pediatric expansion of Tremfya created new biologic options for children with moderate-to-severe psoriasis. Long-term extension studies for Bimzelx presented at the 2025 American Academy of Dermatology meeting reinforced durable efficacy over several years, strengthening its clinical positioning. Strategic acquisitions, such as AbbVie’s acquisition of Nimble Therapeutics, indicate a growing focus on oral IL-23 receptor inhibitors, aiming to simplify dosing and improve adherence. Biosimilars, including SELARSDI in the U.S. and Pyzchiva in Europe, are altering economics and increasing accessibility while providing innovative self-administration options. Emerging oral molecules, like Alumis’ ESK-001 and Johnson & Johnson’s submitted icotrokinra, demonstrate the industry’s push toward effective pill-based systemic therapies, challenging the historical dominance of injectable biologics. Across clinical research, head-to-head trials and real-world data are shaping guideline updates and influencing prescriber behavior, highlighting the market’s emphasis on therapy durability, safety, and patient convenience. The competitive landscape now integrates dual-cytokine inhibitors, small molecules, and established TNF-alpha blockers, reflecting a mature yet rapidly evolving ecosystem driven by innovation, regulatory advances, and patient-centered treatment strategies. .

Market Dynamic

Psoriasis Treatment Market Research Report, 2026-31Segmentation

Psoriatic arthritis is the fastest-growing type in the global psoriasis treatment market due to its increasing recognition as a systemic and debilitating comorbidity requiring early and aggressive intervention.

Psoriatic arthritis has gained considerable attention in recent years because it affects a significant portion of patients with psoriasis and is associated with irreversible joint damage and functional impairment if left untreated. Advances in diagnostic criteria and awareness among dermatologists and rheumatologists have led to earlier detection, with tools like the CASPAR criteria and musculoskeletal ultrasound helping identify joint involvement even in mild or subclinical cases. Clinical guidelines from the American College of Rheumatology and European Alliance of Associations for Rheumatology now emphasize early intervention to prevent structural damage, which has driven treatment initiation for patients previously untreated. Biologic therapies, especially IL-17 and IL-23 inhibitors, have demonstrated profound efficacy in both skin clearance and joint symptom control, making them preferred options for psoriatic arthritis management. Post-marketing studies for drugs like secukinumab, ixekizumab, and guselkumab have reported sustained improvement in pain, swelling, and quality of life, reinforcing confidence among healthcare providers. Patient registries, including the Corrona Psoriasis Registry and the British Society for Rheumatology PsA Register, provide real-world evidence highlighting the burden of psoriatic arthritis and the benefits of comprehensive therapy, further motivating early adoption. Additionally, increasing patient awareness of the risk of joint involvement through educational campaigns and advocacy programs has contributed to more frequent clinical consultations and treatment uptake. The convergence of better diagnostic tools, guideline-driven therapy escalation, strong clinical data for joint-targeted biologics, and patient-driven demand has positioned psoriatic arthritis as a primary focus within psoriasis care, driving its accelerated growth relative to other disease subtypes.

Interleukin inhibitors are the fastest-growing drug class in the global psoriasis treatment market because they offer highly targeted immune modulation with superior efficacy and long-term disease control.

Interleukin inhibitors have transformed the therapeutic landscape for psoriasis by directly targeting cytokines such as IL-17, IL-12/23, and IL-23, which are central to disease pathogenesis. Their mechanism allows for significant reductions in skin lesions and symptom severity while maintaining favorable safety profiles, making them highly attractive to clinicians and patients. Drugs like secukinumab, ixekizumab, guselkumab, risankizumab, and bimekizumab have consistently demonstrated rapid onset of action and sustained skin clearance in both pivotal clinical trials and long-term extension studies. The ability of interleukin inhibitors to achieve high rates of PASI 90 and PASI 100 responses has shifted treatment expectations, prompting guideline updates from the American Academy of Dermatology and the European Academy of Dermatology and Venereology that recommend biologic therapy earlier in moderate-to-severe disease. Post-marketing real-world evidence supports their effectiveness across diverse patient populations, including those with comorbidities such as psoriatic arthritis, cardiovascular risk, and metabolic syndrome, enhancing their clinical adoption. Innovations in dosing schedules, including extended dosing intervals and subcutaneous delivery devices, have improved patient adherence and convenience. Pharmaceutical companies have also invested heavily in global access programs and educational initiatives, enabling widespread adoption in both developed and emerging markets. The combination of proven efficacy, strong safety data, simplified administration, and supportive real-world evidence has solidified interleukin inhibitors as the fastest-growing drug class, reflecting a shift toward precision-targeted therapy in modern psoriasis management.

Biologics drugs are the fastest-growing treatment type in the global psoriasis treatment market because they provide highly effective and durable disease control, addressing both skin and joint manifestations.

Biologics have revolutionized psoriasis treatment by offering therapies that specifically target immune pathways responsible for chronic inflammation, including TNF-alpha, IL-17, and IL-23. Their precision has led to significantly higher rates of skin clearance and joint symptom improvement compared with conventional systemic therapies, making them indispensable for moderate-to-severe cases. Products like adalimumab, secukinumab, guselkumab, and bimekizumab have shown long-term efficacy in pivotal trials and post-marketing studies, with durable responses extending for several years, which is particularly important for chronic management. The rise of patient registries such as the British Association of Dermatologists Biologics and Immunomodulators Register and the Corrona Psoriasis Registry has generated real-world evidence supporting long-term safety, persistence, and quality-of-life improvements, encouraging prescribers to prioritize biologics over traditional therapies. Advances in formulation and delivery, including pre-filled autoinjectors and extended dosing schedules, have enhanced patient convenience and adherence, while pediatric and comorbidity-specific approvals have expanded eligible populations. The combination of superior efficacy, sustained outcomes, real-world validation, and broader patient access has cemented biologics as the most rapidly adopted treatment type, driving their growth in markets worldwide.

Oral administration is the fastest-growing mode in the global psoriasis treatment market because it offers convenient, non-invasive treatment options that improve patient adherence and access to systemic therapy.

Oral therapies for psoriasis, including TYK2 inhibitors such as deucravacitinib and emerging agents like icotrokinra, have gained attention for their ability to provide systemic immune modulation without injections. Patients often prefer oral treatments due to ease of use, reduced clinic visits, and the perception of less invasiveness compared with injectable biologics, which can improve long-term adherence and satisfaction. Clinical trials have demonstrated meaningful efficacy with PASI 75 and PASI 90 responses, comparable to certain biologics, making them viable alternatives for moderate-to-severe disease. Regulatory approvals for pediatric and adult populations, along with supportive long-term safety data, have facilitated broader adoption in multiple regions. The oral route also supports telemedicine and home-based care initiatives, which became particularly important during the COVID-19 pandemic, allowing patients to initiate and maintain treatment remotely. Pharmaceutical companies are developing user-friendly dosing regimens and combination approaches to enhance convenience and minimize adverse effects. Collectively, the combination of clinical effectiveness, patient preference, safety, and accessibility has established oral therapies as the fastest-growing administration route in the global psoriasis treatment landscape.

e-Commerce is the fastest-growing distribution channel in the global psoriasis treatment market because it provides convenient access to therapies, especially in regions with limited dermatology infrastructure or restricted clinic access.

Online sales platforms have expanded rapidly, allowing patients to order prescription and non-prescription psoriasis treatments from home, bypassing geographical and logistical barriers. The trend is particularly notable in North America, Europe, and parts of Asia-Pacific, where telehealth services integrate with e-commerce to facilitate consultations, prescriptions, and home delivery. Digital pharmacies and dedicated psoriasis portals offer patient education, adherence support, and convenient subscription models, which improve consistent therapy use and reduce treatment gaps. The rise of secure online prescription verification, coupled with patient preference for privacy and convenience, has further accelerated adoption. E-commerce also allows rapid introduction of new therapies, including oral medications and topicals, without requiring extensive clinic-based distribution networks. These platforms enhance accessibility for patients in rural or underserved areas, reduce delays in treatment initiation, and support ongoing disease management through repeat orders and adherence monitoring. Pharmaceutical companies and specialty distributors are investing in online marketplaces and patient engagement platforms to maintain competitive advantage, reflecting the increasing reliance on digital channels for treatment procurement. The combination of convenience, patient empowerment, and streamlined logistics has made e-commerce the fastest-growing distribution channel for psoriasis therapies globally.

Psoriasis Treatment Market Research Report, 2026-31 Market Regional Insights

APAC is the fastest-growing region in the global psoriasis treatment market because rising awareness, improved healthcare infrastructure, and expanding access to advanced therapies are driving increased diagnosis and treatment adoption.

Asia-Pacific has seen growing attention to psoriasis management due to improved diagnostic capabilities, higher dermatology clinic density in urban centers, and the establishment of national registries in countries such as Japan, South Korea, and Australia. Governments are increasingly integrating psoriasis care into public health initiatives, while private insurance coverage and hospital-based specialty programs are expanding access to biologics and oral therapies. The region also benefits from pharmaceutical companies prioritizing emerging markets, with approvals for interleukin inhibitors, oral TYK2 inhibitors, and biosimilars accelerating availability. Clinical awareness campaigns and patient advocacy groups are promoting early detection and adherence to guideline-recommended therapy, while teledermatology and e-commerce platforms are reducing access barriers in rural areas. Real-world studies in Japan and Australia have highlighted the benefits of biologics and targeted oral therapies in improving quality of life and functional outcomes, reinforcing adoption among clinicians and patients. Combined with rising disposable incomes and increased willingness to invest in long-term disease management, these factors position the Asia-Pacific region as the fastest-growing market globally, with accelerated uptake across multiple treatment modalities and patient segments.